沙库巴曲缬沙坦治疗慢性心功能不全的临床效果观察

Abstract
Figure/Table
References (19)
Related Citation (15)

Download: PDF (0 KB) HTML (35 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Sacubitril/valsartan treating chronic cardiac insufficiency.Methods A total of 30 cases with chronic cardiac insufficiency treated in our hospital from June to October 2017 were selected as the research subjects.All patients were treated by Sacubitril/valsartan on the basis of the conventional therapy.Standardized continuous treatment lasted for 3 months.The total effective rate for treatment of the patients was observed.The cardiac function indexes,plasma N terminal pro brain natriuretic peptide (NT-proBNP)level and quality of life were compared before and after treatment in patients.Results After treatment,15 cases were markedly effective,13 cases were effective,2 cases were invalid,and the total effective rate was 93.33%.After treatment,the LVEF,FS and KCCQ score were significantly higher than those before treatment,and NT-proBNP level decreased significantly compared with that before treatment,and the difference between the two groups were statistically significant(P<0.01).The incidence of adverse reactions was 10.00%.Conclusion Sacubitril/valsartan treating chronic cardiac insufficiency can improve cardiac function and decrease the level of NT-proBNP in patients,and it is safe and reliable,and it can significantly improve their quality of life.It is worthy of clinical promotion.

Key words： Sacubitril/valsartan Chronic cardiac insufficiency Cardiac function Quality of life

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHOU Hong
	HUANG Si-bing

Cite this article:

ZHOU Hong,HUANG Si-bing. Clinical effect observation of Sacubitril/valsartan treating chronic cardiac insufficiency[J]. 中国当代医药, 2018, 25(19): 51-53.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I19/51

[1]	Tsuji Y，Ishikawa T，Makita N，et al.Molecular mechanisms of heart failure progression associated with implantable cardioverter-defibrillator shocks for ventricular tachyarrhythmias[J].J Arrhythm，2014，30（4）：235-241.
[2]	Pasini E，Aquilani R，Testa C，et al.Pathogenic gut flora in patients with chronic heart failure[J].JACC Heart Fail，2016，4（3）： 220-227.
[3]	Korb H，Adrian A，Baden D，et al.219 Effectivity of telemonitoring in chronic heart insufficiency （CHF） with special regard to clinical and economical aspects[J].Eur J Heart Fail，2015，4（S1）：43-44.
[4]	唐文栋，沈健，赵仙先.沙库必曲/缬沙坦治疗心力衰竭研究概述[J].心血管病学进展，2017，38（4）：407-410.
[5]	Li J，Li Y，Wang XZ，et al.Influence of cardiac insufficiency on acute renal impairment induced by contrast medium in patients with diabetes and renal dysfunction[J].Medicine（Baltimore），2015，40（9）：727-732.
[6]	郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社，2002.
[7]	王学忠.缬沙坦/沙库比曲在心力衰竭临床治疗中的应用[J].中华心血管病杂志，2017，45（6）：538-541.
[8]	Scherer M，Hansen H，Gensichen J，et al.Association between multimorbidity patterns and chronic pain in elderly primary care patients：a cross-sectional observational study[J].BMC Fam Pract，2016，17：68.
[9]	Bianucci R，Loynes RD，Sutherland ML，et al.Forensic analysis reveals acute decompensation of chronic heart failure in a 3500-year-old Egyptian dignitary[J].J Forensic Sci，2016，61（5）：1378-1381.
[10]	Lu H，Behm M，Cornell A，et al.Evaluation of flexible Li4Ti5O12anode electrodes using water-based binder for Li-Ion batteries[J].Anne Med Interne(Paris)，2015，136（3）：266-271.
[14]	李欣，雷兵团，李超.首创的双效血管紧张素受体-脑啡肽酶抑制药沙库必曲/缬沙坦概述[J].中国药师，2016，19（6）：1167-1169.
[19]	张朝当，刘平，田敏卿，等.心血管领域复方创新药的范例：缬沙坦沙库比曲片与依那普利叶酸片——给我国新药创制带来的启示[J].药学进展，2016，40（2）：83-88.
[11]	Chen TH，Chen MR，Chen TY，et al.Cardiac fibrosis in mouse expressing DsRed tetramers involves chronic autophagy and proteasome degradation insufficiency[J].Oncotarget，2016，7（34）：54 274-54 289.
[12]	Topolyanskaya SV，Osipovskaya IO，Lifanova LS，et al.Mineral density and metabolism of bone tissue in patients with chronic heart failure insufficiency of senior age[J].Arch Intern Med，2017，7（3）：205-211.
[13]	Luz PR，Miyazaki MI，Chiminacio Neto N，et al.Genetically determined MBL deficiency is associated with protection against chronic cardiomyopathy in chagas disease[J].PLoS Negl Trop Dis，2016，10（1）：e0004257.
[15]	Feng X，Wu Y，Meng Y，et al.Efficacy and safety of intravenous recombinant human brain natriuretic peptide in patients with severe heart failure：a prospective multicenter clinical study[J].Zhonghua Wei Zhong Bing Ji Jiu Yi Xue，2017，29（6）：520.
[16]	Xin W，Lin Z，Mi S.Does B-type natriuretic peptide-guided therapyimproveoutcomesinpatientswithchronicheart failure?A systematic review and meta-analysis of randomized controlled trials[J].Heart Fail Rev，2015，20（1）：69-80.
[17]	Dieval C，Deligny C，Meyer A，et al.Myocarditis in patients with antisynthetase syndrome：prevalence，presentation，and outcomes[J].Medicine，2015，94（26）：e798.
[18]	Wu B，Ma L，Shao Y，et al.Effect of cardiac surgery-associated acute kidney injury on long-term outcomes of Chinese patients： a historical cohort study[J].Blood Purif，2017，44（3）：227-233.